固摄扶正抗癌汤联合阿法替尼、培美曲塞治疗非小细胞肺癌的临床效果观察  

Clinical Effect of Gushe Fuzheng Anticancer Decoction Combined with Afatinib and Pemetrexed in Treatment of Patients with Non-small Cell Lung Cancer

作　　者：肖敬 程晓云[1] 张淑平 安永献 韩文峰[1] 周红梅[1] 赵艳勋[2] XIAO Jing;CHENG Xiao-yun;ZHANG Shu-ping;AN Yong-xian;HAN Wen-feng;ZHOU Hong-mei;ZHAO Yan-xun(Department of Oncology,the Seventh People's Hospital of Hebei Province,Baoding,Hebei 073000,China;Department of Oncology,General Hospital of North China Petroleum Administration Bureau,Cangzhou,Hebei 062550,China)

机构地区：[1]河北省第七人民医院肿瘤内科,河北保定073000 [2]华北石油管理局总医院肿瘤科,河北沧州062550

出　　处：《解放军医药杂志》2019年第11期20-23,共4页Medical & Pharmaceutical Journal of Chinese People’s Liberation Army

基　　金：河北省中医药管理局科研计划项目(2018515)

摘　　要：目的探讨固摄扶正抗癌汤联合阿法替尼、培美曲塞治疗非小细胞肺癌的临床效果。方法收集2017年1月-2019年2月来我院治疗的晚期非小细胞肺癌120例,按照治疗方法分为A组、B组、C组,每组40例。A组给予顺铂联合培美曲塞化疗,B组给予培美曲塞联合阿法替尼治疗,C组在B组基础上给予固摄扶正抗癌汤。观察并比较3组治疗后免疫功能、临床效果、不良反应发生情况及生活质量的差异。结果 C组临床总有效率显著优于A组和B组,且B组优于A组(P<0.01)。3组治疗后CD3^+、CD4^+、CD4^+/CD8^+值高于治疗前, CD8^+百分率低于治疗前,且C组上述指标优于A组和B组(P<0.05)。3组不良反应比较差异无统计学意义(P>0.05)。3组生活质量评分高于治疗前,且C组优于A组和B组(P<0.05)。结论固摄扶正抗癌汤联合阿法替尼、培美曲塞治疗非小细胞肺癌的临床效果更好,能有效缓解患者症状,提高患者的生存质量。Objective To investigate clinical effect of Gushe Fuzheng Anticancer Decoction combined with Afatinib and Pemetrexed in treatment of patients with non-small cell lung cancer. Methods A total of 120 patients with advanced non-small cell lung cancer treated during January 2017 and February 2019 were divided into group A, group B and group C(n=40 in each group) according to therapeutic methods. Group A was treated with Cisplatin combined with Pemetrexed, while group B was treated with Pemetrexed combined with Alfatinib, and group C was added with Gushe Fuzheng Anticancer Decoction on the basis of treatment for group B. Differences in immune function, clinical effect, incidence rate of adverse reactions and life quality after treatment among three groups were observed and compared. Results The total clinical effective rate in group C was significantly higher than those in group A and B, and the rate in group B was significantly higher than that in group A(P<0.01). After treatment among three groups, percentages of CD3^+, CD4^+ and CD4^+/CD8^+ were significantly higher, while CD8^+ percentages were significantly lower than those before treatment, and the above indexes in group C were significantly better than those in group A and B(P<0.05). There was no significant differences in incidence rate of adverse reactions among three groups(P>0.05). Score of life quality after treatment were significantly higher than those before treatment among three groups, and the score in group C was significantly higher than those in group A and B(P<0.05). Conclusion Clinical effects by three different therapeutic methods for non-small cell lung cancer have been improved. Among them, Gushe Fuzheng Anticancer Decoction combined with Afatinib and Pemetrexed has better clinical effect and fewer side effects, and it may effectively alleviate clinical symptoms and improve survival rate.

关 键 词：癌 非小细胞肺 阿法替尼 培美曲塞 固摄扶正抗癌汤 治疗结果 

分 类 号：R730.26[医药卫生—肿瘤]